Kaouthar Lbiati
Director/Board Member at HEPION PHARMACEUTICALS, INC.
Net worth: - $ as of 2024-03-30
Profile
Kaouthar Lbiati is currently an Independent Director at Hepion Pharmaceuticals, Inc. and Theralase Technologies, Inc. She is also the Vice President of Strategy & Corporate Development at Cytovia Therapeutics, Inc. She has a graduate degree from the London School of Economics & Political Science and ESSEC Business School.
She also holds a doctorate degree from Mohammed V University.
Known holdings in public companies
Company | Date | Number of shares | Valuation | Valuation date |
---|---|---|---|---|
2024-02-18 | 0 ( -.--% ) | - $ | 2024-03-30 | |
2023-09-20 | 0 ( -.--% ) | - $ | 2024-03-30 |
Kaouthar Lbiati active positions
Companies | Position | Start |
---|---|---|
HEPION PHARMACEUTICALS, INC. | Director/Board Member | 2022-06-26 |
THERALASE TECHNOLOGIES INC. | Director/Board Member | 2023-06-05 |
Cytovia Therapeutics, Inc.
Cytovia Therapeutics, Inc. BiotechnologyHealth Technology Cytovia Therapeutics, Inc. engages in transformational immunotherapies for cancer and severe acute infectious diseases. Its products include Multi-Specific NK Engager Antibodies and iPSC CAR NK cells. The company was founded by Daniel Teper, Gilles Seydoux, and Massimo Radaelli and is headquartered in New York, NY. | Corporate Officer/Principal | - |
Former positions of Kaouthar Lbiati
Companies | Position | End |
---|---|---|
IMMUNE PHARMACEUTICALS, INC. | Corporate Officer/Principal | - |
Steba Biotech SA
Steba Biotech SA Miscellaneous Commercial ServicesCommercial Services Steba Biotech SA is a Luxembourger biotechnology company that focuses on developing therapies to combat cancer. The private company is based in Luxembourg, Luxembourg. | Corporate Officer/Principal | - |
Training of Kaouthar Lbiati
London School of Economics & Political Science | Graduate Degree |
ESSEC Business School | Graduate Degree |
Mohammed V University | Doctorate Degree |
Experiences
Positions held
Connections
1st degree connections
1st degree companies
Male
Female
Members of the board
Executives
Linked companies
Listed companies | 1 |
---|---|
HEPION PHARMACEUTICALS, INC. | Health Technology |
Private companies | 4 |
---|---|
Theralase Technologies, Inc. | |
Immune Pharmaceuticals, Inc.
Immune Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Immune Pharmaceuticals, Inc. is a biopharmaceutical company developing novel therapeutic agents for the treatment of immunologic and inflammatory diseases. Its lead product, Bertilimumab, is a human monoclonal antibody that binds eotaxin-1, a chemokine that attracts eosinophils to the site of inflammation. Bertilimumab has shown promising clinical activity in bullous pemphigoid and has been studied in other conditions including allergic rhinitis and ulcerative colitis, and may have application in other diseases, including atopic dermatitis, asthma, and other diseases. It is also developing NanoCyclo, a topical nano-encapsulated formulation of cyclosporine, for the treatment of atopic dermatitis (AD) and psoriasis. The company was founded by Daniel Gedeon Teper on March 9, 1993 and is headquartered in Englewood Cliffs, NJ. | Health Technology |
Steba Biotech SA
Steba Biotech SA Miscellaneous Commercial ServicesCommercial Services Steba Biotech SA is a Luxembourger biotechnology company that focuses on developing therapies to combat cancer. The private company is based in Luxembourg, Luxembourg. | Commercial Services |
Cytovia Therapeutics, Inc.
Cytovia Therapeutics, Inc. BiotechnologyHealth Technology Cytovia Therapeutics, Inc. engages in transformational immunotherapies for cancer and severe acute infectious diseases. Its products include Multi-Specific NK Engager Antibodies and iPSC CAR NK cells. The company was founded by Daniel Teper, Gilles Seydoux, and Massimo Radaelli and is headquartered in New York, NY. | Health Technology |
- Stock Market
- Insiders
- Kaouthar Lbiati